Astal Laboratories Limited

BSE: 512600
Astal Laboratories Limited - pharma in Noida, Uttar Pradesh, India. FY 2026 financials & compliance.
CIN L74120UP1993PLC015605 Incorporated 03 August 1993 ROC Uttar Pradesh HQ Noida, Uttar Pradesh, India
Active Listed - BSE: 512600 Public Limited Company pharma
Data last updated
Market Cap
₹235 Cr
ASTALLTD · BSE
Share Price
₹51.25
-4.58% today
Revenue
₹250 Cr
FY 2025-26 · +289.5% YoY
EBITDA
₹20.77 Cr
Margin 8.3%
Net Profit
₹14.71 Cr
FY 2025-26 · +64.5% YoY
P/E (TTM)
18.4x
P/B 0.8x
ROE
8.0%
ROCE 9.1%
Debt / Equity
0.17
Interest cover 10.4x

About Astal Laboratories Limited

Data last updated:

Astal Laboratories Limited is a public limited company based in Noida, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 August 1993 and has been in existence for over 33 years.

The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN L74120UP1993PLC015605. Its GSTIN is 36AAACM9288K1ZU (Telangana). It is a listed company as per MCA records. Its shares are listed on BSE: 512600.

The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹43.8 Cr. It was formerly known as Macro (International) Exports Limited. It is led by directors including Sudheer Karna Kankanala (Whole-Time Director) and Birendrakumar Sahoo.

Its last annual general meeting (AGM) was held on 12 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Office No. B7 A – 40 Sector 4, Noida, Uttar Pradesh, India – 201301.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹250.15 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹14.71 Cr (net margin 5.9%) and EBITDA of ₹20.77 Cr (EBITDA margin 8.3%). The net worth stands at ₹333.76 Cr (up 827.1% YoY). Total assets are valued at ₹383.49 Cr (up 678.5% YoY).

The company is associated with 1 brand: Macro International. As per MCA filings, the company has open charges of ₹14.1 Cr and satisfied charges of ₹2.46 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 24 deals on record (24 market trades); the latest was in October 2024. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Valary Lab Private Limited with revenue of ₹65.12 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website miel.co.in.

Company details

CIN L74120UP1993PLC015605
Registration Number 015605
Incorporation Date 03 August 1993
ROC Uttar Pradesh
Listing Status Listed - Listed on BSE (512600)
Company Status Active
Date of Last AGM 12 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Astal Laboratories has one previous CIN (Corporate Identification Number): L16001UP1993PLC015605. The current CIN is L74120UP1993PLC015605, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74120UP1993PLC015605Current
L16001UP1993PLC015605Previous
Key People
Sudheer Karna Kankanala Whole-Time Director Birendrakumar Sahoo Director Ravikanti Shailaja Director

Contact details

Astal Laboratories Limited's registered office is in Noida, Uttar Pradesh. Its website is miel.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    miel.co.in
  • Registered Address
    Office No. B7 A – 40 Sector 4, Noida, Uttar Pradesh, India – 201301
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Astal Laboratories Limited, buy the company report.

Comprehensive company report
Astal Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Astal Laboratories operates one associated brand: Macro International. Each brand links to its own profile.

BrandDescriptionWebsite
Macro International
Multiple real estate strategies are focused on by the firm.miel.co.in

Business activity

The main business activity of Astal Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Astal Laboratories Limited, buy the company report.

Financials of Astal Laboratories Limited

FY 2025-26 filings available

Astal Laboratories Limited reported revenue of ₹250.15 Cr (up 289.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹250 Cr
+289.5% YoY
EBITDA
₹20.77 Cr
+62.5% YoY
Profit After Tax
₹14.71 Cr
+64.5% YoY
Net Worth
₹334 Cr
+827.1% YoY
Total Assets
₹383 Cr
+678.5% YoY
Total Debt
₹49.08 Cr
+269.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25
Income statement
Revenue25064.23
Revenue growth+289.5%-
EBITDA20.7712.78
EBITDA margin+8.3%+19.9%
Profit before tax17.7311.99
Net profit14.718.94
Net profit margin+5.9%+13.9%
EPS (₹)3.489.07
Balance sheet
Total assets38349.26
Net worth33436.00
Total debt49.0813.27
Cash & bank0.701.73
Net working capital10931.68
Cash flow
Cash from operations(17.70)(12.52)
Cash from investing(2.17)(7.81)
Cash from financing2.583.29
ParticularsJun 2026Mar 2026Dec 2025Mar 2025
Revenue10113452.2423.47
Revenue growth (YoY)-+471.2%--
Other income0.140.100.040.04
EBITDA12.2510.193.564.19
EBITDA margin+12.1%+7.6%+6.8%+17.9%
Depreciation0.860.860.120.10
Interest1.181.090.330.27
Profit before tax10.358.343.153.86
Tax0.930.660.771.10
Net profit9.427.682.382.76
EPS (₹)2.181.951.741.77
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue15664.2323.653.430.000.200.00
Revenue growth+142.9%+171.6%+589.5%--100.0%--
EBITDA12.7812.781.11(0.13)(0.23)0.02(0.22)
EBITDA margin+8.2%+19.9%+4.7%-3.8%-+10.0%-
Profit before tax10.8711.991.080.04(0.03)0.00(0.04)
Net profit8.128.940.780.02(0.03)0.00(0.04)
Net profit margin+5.2%+13.9%+3.3%+0.6%-0.0%-
EPS (₹)4.319.070.800.04(0.04)0.02(0.07)
Balance sheet
Total assets34049.2623.655.185.165.185.17
Net worth32736.0023.345.185.165.185.17
Total debt11.9613.270.310.000.000.000.00
Cash & bank0.701.736.080.080.020.030.01
Net working capital43.7531.6813.791.390.03(0.01)5.03
Cash flow
Cash from operations(3.08)(12.52)(5.58)(1.44)(0.25)(0.19)(0.20)
Cash from investing(1.28)(7.81)(6.11)1.500.240.200.20
Cash from financing4.553.2917.680.000.000.000.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.5140.9252.2437.5225.3323.4714.4613.16
Revenue growth (YoY)+56.0%+74.4%+261.3%+185.1%+92.6%---
Other income0.030.070.040.030.060.040.060.00
Total expenses34.0838.7248.6833.6522.1719.2811.1310.27
EBITDA5.432.203.563.873.164.193.332.89
EBITDA margin+13.7%+5.4%+6.8%+10.3%+12.5%+17.9%+23.0%+22.0%
Depreciation0.180.320.120.120.120.100.080.03
Interest0.330.470.330.310.300.270.280.09
Profit before tax4.951.483.153.472.803.863.032.77
Tax1.250.390.770.880.711.100.530.77

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 03 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Mar 2025
Revenue10113452.2423.47
Revenue growth (YoY)-+471.2%--
Other income0.140.100.040.04
EBITDA12.2510.193.564.19
EBITDA margin+12.1%+7.6%+6.8%+17.9%
Depreciation0.860.860.120.10
Interest1.181.090.330.27
Profit before tax10.358.343.153.86
Tax0.930.660.771.10
Net profit9.427.682.382.76
EPS (₹)2.181.951.741.77
ParticularsFY 2025-26FY 2024-25
Revenue25064.23
Revenue growth+289.5%-
Other income0.220.13
Total expenses22951.45
Employee cost5.031.26
EBITDA20.7712.78
EBITDA margin+8.3%+19.9%
Depreciation1.230.22
Interest2.030.70
Profit before tax17.7311.99
Tax3.023.05
Net profit14.718.94
Net profit margin+5.9%+13.9%
EPS (₹)3.489.07
ParticularsFY 2025-26FY 2024-25
Equity & liabilities
Share capital42.239.85
Reserves & surplus28922.42
Shareholders' funds (net worth)33436.00
Minority interest0.000.00
Secured loans48.1913.27
Unsecured loans0.890.00
Total debt49.0813.27
Total liabilities38349.26
Assets
Gross block69.9211.77
Net block64.4611.44
Capital work in progress0.000.00
Investments2030.00
Inventories67.5214.76
Sundry debtors15727.66
Cash & bank balances0.701.73
Loans & advances18.041.49
Total current assets24345.64
Total current liabilities13413.96
Net working capital10931.68
Total assets38349.26
ParticularsFY 2025-26FY 2024-25
Opening cash(10.96)6.08
Net cash from operating activities(17.70)(12.52)
Net cash from investing activities(2.17)(7.81)
Net cash from financing activities2.583.29
Net change in cash(17.29)(17.04)
Closing cash0.701.73
ParticularsFY 2025-26FY 2024-25
Growth
Sales growth+289.5%-
EBITDA growth+62.5%-
PBT growth+47.9%+9997.0%
Net income growth+64.5%-
Profitability & leverage
Net income margin+5.9%+13.9%
Return on capital employed+9.1%+25.7%
Return on net worth+8.0%+24.8%
Debt / equity0.170.37
Long-term debt / equity0.050.01
Interest cover10.395.57
Efficiency & per share
Fixed asset turnover6.125.46
Inventory turnover6.084.35
Debtors turnover2.712.32
EPS (₹)3.489.07
Dividend per share (₹)0.000.00
Book value per share (₹)78.5432.77
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.5140.9252.2437.5225.3323.4714.4613.16
Revenue growth (YoY)+56.0%+74.4%+261.3%+185.1%+92.6%---
Other income0.030.070.040.030.060.040.060.00
Total expenses34.0838.7248.6833.6522.1719.2811.1310.27
EBITDA5.432.203.563.873.164.193.332.89
EBITDA margin+13.7%+5.4%+6.8%+10.3%+12.5%+17.9%+23.0%+22.0%
Depreciation0.180.320.120.120.120.100.080.03
Interest0.330.470.330.310.300.270.280.09
Profit before tax4.951.483.153.472.803.863.032.77
Tax1.250.390.770.880.711.100.530.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue15664.2323.653.430.000.200.00
Revenue growth+142.9%+171.6%+589.5%--100.0%--
Other income0.190.130.010.180.210.000.20
Total expenses14351.4522.543.560.230.180.22
Employee cost0.001.260.470.060.090.060.09
EBITDA12.7812.781.11(0.13)(0.23)0.02(0.22)
EBITDA margin+8.2%+19.9%+4.7%-3.8%-+10.0%-
Depreciation0.690.220.030.010.010.020.02
Interest1.410.700.010.000.000.000.00
Profit before tax10.8711.991.080.04(0.03)0.00(0.04)
Tax2.753.050.300.020.000.000.00
Net profit8.128.940.780.02(0.03)0.00(0.04)
Net profit margin+5.2%+13.9%+3.3%+0.6%-0.0%-
EPS (₹)4.319.070.800.04(0.04)0.02(0.07)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital42.239.859.853.993.993.993.99
Reserves & surplus28322.4213.491.191.171.191.18
Shareholders' funds (net worth)32736.0023.345.185.165.185.17
Secured loans11.8413.150.310.000.000.000.00
Unsecured loans0.120.120.000.000.000.000.00
Total debt11.9613.270.310.000.000.000.00
Total liabilities34049.2623.655.185.165.185.17
Assets
Gross block13.1211.770.790.080.080.170.17
Net block12.1011.440.690.010.010.050.07
Capital work in progress0.000.000.000.000.000.000.00
Investments2770.000.000.000.000.000.00
Inventories28.7814.761.060.000.000.000.00
Sundry debtors72.3027.6615.823.170.000.000.00
Cash & bank balances0.701.736.080.080.020.030.01
Loans & advances1.491.493.782.870.080.095.12
Total current assets10345.6426.746.120.100.125.13
Total current liabilities59.5213.9612.954.730.070.130.10
Net working capital43.7531.6813.791.390.03(0.01)5.03
Total assets34049.2623.655.185.165.185.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(10.96)6.080.080.020.030.010.01
Net cash from operating activities(3.08)(12.52)(5.58)(1.44)(0.25)(0.19)(0.20)
Net cash from investing activities(1.28)(7.81)(6.11)1.500.240.200.20
Net cash from financing activities4.553.2917.680.000.000.000.00
Net change in cash0.19(17.04)5.990.07(0.01)0.020.01
Closing cash0.701.736.080.080.020.030.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+142.9%+171.6%+589.5%--100.0%--
EBITDA growth0.0%+1051.4%+953.9%+43.5%-1250.0%+109.1%-
PBT growth-9.3%+1010.2%+2600.0%+9998.0%+9997.0%+9997.0%+50.0%
Net income growth-9.2%+1046.2%+3800.0%+166.7%-+100.0%-
Revenue CAGR (3Y)+257.0%-+390.8%----
EBITDA CAGR (3Y)--+281.4%-16.1%-13.9%--7.7%
Profitability & leverage
Net income margin+5.2%+13.9%+3.3%+0.6%-0.0%-
Return on capital employed-+34.8%+7.6%+0.8%-0.2%+0.2%-0.6%
Return on net worth-+30.1%+5.5%+0.4%-0.4%+0.2%-0.6%
Debt / equity-0.230.010.000.000.000.00
Long-term debt / equity-0.010.010.000.000.000.00
Interest cover11.665.570.930.000.00-0.00
Efficiency & per share
Fixed asset turnover-10.2354.3742.880.001.180.00
Inventory turnover-8.1244.620.000.000.000.00
Debtors turnover-2.952.492.160.000.000.00
EPS (₹)4.319.070.800.04(0.04)0.02(0.07)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0032.7723.7112.9812.9312.9712.96

To see the full year-wise statements and ratios of Astal Laboratories Limited, buy the company report.

Board of directors of Astal Laboratories Limited

Astal Laboratories has 7 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Birendrakumar Sahoo
Also directs: Anand Life Sciences LLP, Manoharamma Hotel Investments Private Limited, Cytozon Technologies Private Limited and 3 more
Director24 May 20242 Years 5 MonthsCurrent
Sudheer Karna Kankanala
Also directs: Alsys Research LLP, Kasner Bio LLP, Zeugen Technologies Private Limited and 1 more
Whole-Time Director08 Sep 20224 Years 1 MonthsCurrent
Ravikanti Shailaja
Also directs: DM Fincon Services LLP, Aceso Research Labs LLP
Director08 Sep 20224 Years 1 MonthsCurrent
Hemachakrapani BangaraiahgariDirector08 Sep 20224 Years 1 MonthsCurrent
Julius Paul Reinhard PaschkeDirector21 Dec 20241 Years 10 MonthsCurrent
Maggidi Venkatesh
Also directs: Hemasree Life Science LLP, Exports Spark Alliance LLP
Director10 Jun 20233 Years 4 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Peer comparison

Astal Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Astal Laboratories Limitedthis company₹250.15 Cr (FY 2026)₹14.71 Cr5.9%289.5%Noida, Uttar Pradesh, India
Valary Lab Private Limited₹65.12 Cr (FY 2025)0.0%Hyderabad, Telangana, India
Kremoint Pharma Private Limited₹64.72 Cr (FY 2025)12.0%Ambernath, Maharashtra, India
Biovivid Labs Pharmaceuticals Private Limited₹64.61 Cr (FY 2025)121.0%Delhi, India
Asiatic Drugs and Pharmaceuticals Private Limited₹64.49 Cr (FY 2025)25.0%New Delhi, Delhi, India
Vision Parenteral Private Limited₹64.47 Cr (FY 2025)8.0%Gorakhpur, Uttar Pradesh, India
Arbro Pharmaceuticals Private Limited₹64.16 Cr (FY 2025)-9.0%Delhi, India
Kilitch Healthcare India Limited₹63.63 Cr (FY 2024)7.0%Mumbai, Maharashtra, India
Sance Laboratories Private Limited₹63.45 Cr (FY 2025)14.0%Kottayam, Kerala, India

To see the full peer comparison of Astal Laboratories Limited, buy the company report.

Auditor

Astal Laboratories Limited is audited by SATHULURI & CO. for the financial year 2023.

Auditor firmFinancial yearFirm registration number
SATHULURI & CO.FY 2023006383S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 4.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 95.50%.

Promoters: 4.50%Retail & Others: 95.50%
Sep 2026
QUARTER
4.50% Promoters
95.50% Retail & Others
Promoter holding - history
Now 4.50% · Sep 2026High 18.20% · Dec 2025Low 4.50% · Sep 2026
3%7.3%11.5%15.8%20%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 18.20%Mar 2026: 18.20%Jun 2026: 4.70%Sep 2026: 4.50%18.20%4.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters4.50%4.70%18.20%18.20%
Public95.50%95.30%81.80%81.80%

Charges & borrowings

Open charges
₹14.1 Cr
Satisfied charges
₹2.46 Cr
Breakdown by lending institutions
Canara Bank₹14.10 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
28 Nov 2024101015539Canara Bank₹9 CrOpen
25 Apr 2024100919386Canara Bank₹5.1 CrOpen
29 Sep 199790276895Canara Bank₹10 LakhSatisfied
29 Sep 199790281236Canara Bank₹10 LakhSatisfied
13 Mar 199690273390Canara Bank₹82 LakhSatisfied

To see the full charge records of Astal Laboratories Limited, buy the company report.

Total charge records: 8 View all charges

Deals & funding

Astal Laboratories Limited has 24 deals on record (24 market trades); the latest was in October 2024.

Total deals
24
Market trades
24

Deals on record (5 of 24)

WhenDealAmountParties
Oct 2024Market trade₹48.8 LakhBuyer: an individual
Sep 2023Market trade₹23.8 LakhBuyer: an individual
Aug 2023Market trade₹42.1 LakhBuyer: an individual
Seller: an individual
May 2023Market trade₹20.6 LakhSeller: an individual
Dec 2016Market trade₹23.4 LakhBuyer: Makesworth Projects & Developers Private Limited

To see the full deal history of Astal Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Astal Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Astal Laboratories has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
36AAACM9288K1ZUTelanganaActive24 Jan 2023

To see the full GST registrations and return filing status of Astal Laboratories Limited, buy the company report.

Recent activity

Astal Laboratories Limited has 28 board changes on record since 1993: 18 appointments and 10 cessations. The latest: Julius Paul Reinhard Paschke was appointed as Director on 21 Dec 2024.

Filing
Astal Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Uttar Pradesh Ii.
AGM
Astal Laboratories Limited last Annual general meeting of members was held on 12 Sep 2025 as per latest MCA records.
Charges
A charge with Canara Bank of Rs. 9.00 Cr registered on 28 Nov 2024 with Charge ID 101015539 was modified on 23 May 2025.
Charges
A charge with Canara Bank of Rs. 5.10 Cr registered on 25 Apr 2024 with Charge ID 100919386 was modified on 23 May 2025.
Appointed
Julius Paul Reinhard Paschke was appointed as Director.
Charges
A charge with Canara Bank amounted to Rs. 9.00 Cr with Charge ID 101015539 was registered on 28 Nov 2024.
Appointed
Birendrakumar Sahoo was appointed as Director.
Charges
A charge with Canara Bank amounted to Rs. 5.10 Cr with Charge ID 100919386 was registered on 25 Apr 2024.
Appointed
Radhakishore Pandrangi was appointed as Director.
Appointed
Balayogiswara Rao Peddinti was appointed as CFO.
Ceased
Lakshmi Narasimha Anand Kumar Kanuparthi ceased to be Additional Director.
Ceased
Chintalapati Sesha Sai Nikhil ceased to be CFO.

38 earlier events are in the company report.

News

Frequently asked questions

Astal Laboratories is an active public limited company based in Noida, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 August 1993 (33+ years old) and is registered under CIN L74120UP1993PLC015605. Listed on BSE: 512600.

Astal Laboratories reported revenue of ₹250.15 Cr for FY 2025-26 (up 289.5% YoY) based on consolidated financials.

Astal Laboratories has 7 current directors:

The latest financial statements of Astal Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 12 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Astal Laboratories is 36AAACM9288K1ZU, registered in Telangana.

The CIN (Corporate Identification Number) of Astal Laboratories is L74120UP1993PLC015605. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Astal Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 512600).

Astal Laboratories has 1 court case on record: 1 filed by the company. 1 is pending.

Astal Laboratories was incorporated on 03 August 1993, making it 33+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.

Astal Laboratories has 24 deals on record (24 market trades); the latest was in October 2024.

The peers of Astal Laboratories by revenue are Valary Lab Private Limited, Kremoint Pharma Private Limited, Biovivid Labs Pharmaceuticals Private Limited, Asiatic Drugs and Pharmaceuticals Private Limited, Vision Parenteral Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).